Ken Griffin Volitionrx LTD Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.5 - $0.76 $3,050 - $4,636	6,100 Added 42.66%	20,400 $12,000
Q2 2024 Aug 14, 2024	BUY	$0.59 - $0.91 $8,437 - $13,013	14,300 New	14,300 $8,000
Q2 2023 Aug 14, 2023	SELL	$1.39 - $2.02 $10,008 - $14,544	-7,200 Reduced 35.12%	13,300 $18,000
Q1 2023 May 15, 2023	SELL	$1.54 - $2.68 $14,784 - $25,728	-9,600 Reduced 31.89%	20,500 $39,000
Q4 2022 Feb 14, 2023	SELL	$1.39 - $2.6 $12,649 - $23,660	-9,100 Reduced 23.21%	30,100 $73,000
Q3 2022 Nov 14, 2022	BUY	$1.36 - $2.38 $16,592 - $29,036	12,200 Added 45.19%	39,200 $53,000

17.8M

41K

100

Ticker VNRX
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 57,297,000
Market Cap $45.3M
Description
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating sampl...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.